Prostate cancer DNA vaccine (Cellectis/Karolinska Institute)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameProstate cancer DNA vaccine (Cellectis/Karolinska Institute)
Drug Alias Name前列腺癌DNA疫苗 - Cellectis/卡罗琳学院pVAXrcPSAv53l
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsGene transference
TargetsProstate-specific antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKarolinska InstitutetCyto Pulse Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUppsala UniversityKarolinska InstitutetCyto Pulse Sciences Inc
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A